Literature DB >> 12525508

Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture.

Britta Bürger1, Martin Zimmermann, Georg Mann, Joachim Kühl, Lutz Löning, Hansjörg Riehm, Alfred Reiter, Martin Schrappe.   

Abstract

PURPOSE: To determine the significance of leukemic blasts or traumatic lumbar puncture (TLP) in diagnostic CSF of children enrolled in the Berlin-Frankfurt-Münster (BFM) Acute Lymphoblastic Leukemia-BFM-95 trial. PATIENTS AND METHODS: A total of 2,021 patients were retrospectively evaluated according to initial central nervous system (CNS) status. Patients were classified as follows: CNS1 (CNS negative, n = 1,605), CNS2 (< or = 5 WBC/ micro L CSF with blasts, n = 103), CNS3 (CNS positive, n = 58), TLP+ (TLP with blasts, n = 135), or TLP- (TLP without blasts, n = 111). Patients with CNS2 and TLP+ status were eligible for two additional doses of intrathecal (IT) methotrexate (MTX). CNS3 patients received additional IT MTX and cranial irradiation (18 Gy).
RESULTS: CNS2, CNS3, and TLP+ groups contained a higher percentage of patients with unfavorable characteristics. Cox regression analysis identified TLP+ and CNS3 status as prognostically significant (CNS3): risk ratio (RR) = 2.3; 95% confidence interval [CI], 1.4 to 3.6; P =.0005; TLP+: RR = 1.5; 95% CI, 1.02 to 2.2; P =.04. Overall 5-year event-free survival (EFS) is 79%, for CNS1 it is 80%, and for TLP- it is 83%. CNS2 patients have an EFS of 80%, but the cumulative incidence of relapses with CNS involvement is higher compared with CNS1 patients (0.10 v 0.04). TLP+ patients have a significantly reduced EFS (73%, P =.003) because of an increased incidence of CNS relapses. CNS3 patients suffer from more systemic and CNS relapses (EFS 50%).
CONCLUSION: CNS2 patients have the same prognosis as patients with CNS1 status, whereas the EFS of TLP+ patients is inferior to CNS1 but superior to CNS3 patients (P =.001). Both subgroups may have benefitted from additional IT MTX.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525508     DOI: 10.1200/JCO.2003.04.096

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  49 in total

1.  Automated Cerebrospinal Fluid Cell Counts Using the New Body Fluid Mode of Sysmex UF-1000i.

Authors:  Sabrina Buoro; Sara Apassiti Esposito; MariaGrazia Alessio; Alberto Crippa; Cosimo Ottomano; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2015-08-24       Impact factor: 2.352

Review 2.  Leukemia and the nervous system.

Authors:  Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2005-01       Impact factor: 5.075

Review 3.  The Use of Ommaya Reservoirs to Deliver Central Nervous System-Directed Chemotherapy in Childhood Acute Lymphoblastic Leukaemia.

Authors:  Ruairi Wilson; Caroline Osborne; Christina Halsey
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

Review 4.  Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

Authors:  Ching-Hon Pui; Eckhard Thiel
Journal:  Semin Oncol       Date:  2009-08       Impact factor: 4.929

5.  Acute lymphoblastic leukemia of the central nervous system: on the role of PBX1.

Authors:  Ameera Alsadeq; Denis M Schewe
Journal:  Haematologica       Date:  2017-04       Impact factor: 9.941

6.  A survey of procedural sedation and analgesia practices in pediatric oncology centers in India.

Authors:  Ramandeep Singh Arora; Ketan P Kulkarni; Robert D Alston
Journal:  Indian J Pediatr       Date:  2012-03-16       Impact factor: 1.967

7.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Yousif Matloub; Bruce C Bostrom; Stephen P Hunger; Linda C Stork; Anne Angiolillo; Harland Sather; Mei La; Julie M Gastier-Foster; Nyla A Heerema; Scott Sailer; Patrick J Buckley; Blythe Thomson; Catherine Cole; James B Nachman; Gregory Reaman; Naomi Winick; William L Carroll; Meenakshi Devidas; Paul S Gaynon
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

8.  Safe lumbar puncture under analgo-sedation in children with acute lymphoblastic leukemia.

Authors:  Palma Maurizi; Ida Russo; Daniela Rizzo; Antonio Chiaretti; Paola Coccia; Giorgio Attinà; Antonio Ruggiero; Riccardo Riccardi
Journal:  Int J Clin Oncol       Date:  2013-02-07       Impact factor: 3.402

9.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Authors:  Sabina Chiaretti; Antonella Vitale; Gianni Cazzaniga; Sonia Maria Orlando; Daniela Silvestri; Paola Fazi; Maria Grazia Valsecchi; Loredana Elia; Anna Maria Testi; Francesca Mancini; Valentino Conter; Geertruy te Kronnie; Felicetto Ferrara; Francesco Di Raimondo; Alessandra Tedeschi; Giuseppe Fioritoni; Francesco Fabbiano; Giovanna Meloni; Giorgina Specchia; Giovanni Pizzolo; Franco Mandelli; Anna Guarini; Giuseppe Basso; Andrea Biondi; Robin Foà
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

10.  Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

Authors:  C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling
Journal:  Leukemia       Date:  2009-12-10       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.